Table 1.
Clinical trials of novel immune checkpoint inhibitor antibodies.
| Regimen | Drug Class | Inclusion Criteria | Phase | Status (March 2023) |
Identifier | ORR | mPFS (Months) |
mOS (Months) |
|---|---|---|---|---|---|---|---|---|
| Retifanlimab | Anti-PD1 | mUC, RCC, melanoma, NSCLC | 2 | Completed | NCT03679767 | 37.9% | 5.7 | 15.2 |
| Sasanlimab | Anti-PD1 | Advanced solid tumors | 1 | Completed | NCT02573259 | 21.1% | 2.9 | 10.9 |
| Tislelizumab | Anti-PD1 | 2L+ mUC after platinum | 2 | Completed | NCT04004221 | 24% | 2.1 | 9.8 |
| Rulonilimab | Anti-PD1 | 1L cis-ineligible or 2L+ mUC | 2 | Unknown | NCT04636515 | NA | NA | NA |
| Toripalimab | Anti-PD1 | 1L mUC | 2 | Unknown | NCT03113266 | 25.8% | 2.3 | 14.4 |
| Socazolimab | Anti-PDL1 | mUC | 1/2 | Unknown | NCT03676946 | NA | NA | NA |
| Tremelimumab | Anti-CTLA4 | mUC after PD1/PDL1 | 2 | Active, not recruiting | NCT03557918 | NA | NA | NA |
Abbreviations: ORR = objective response rate; mPFS = median progression-free survival; mOS = median overall survival; mUC = metastatic urothelial carcinoma; RCC = renal cell carcinoma, NSCLC = non-small-cell lung carcinoma; 2L+ = second line or beyond; 1L = first line; NA = not available.